Allogene’s $110M offering; Apellis refinances

Plus, news about FogPharma, Artbio, Enveric, MindBio and Allozymes:

Allogene taps investors for $110M: The biotech priced a common stock offering that included mutual funds, institutional investors and healthcare specialists. Some board members and executives also took part in the financing. The Bay Area biotech now has rights in the EU and UK for the allogeneic cell therapy called cemacabtagene ansegedleucel. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

MSOS Stock Analysis – Waiting for the next move with cannabis stocks & MSOS stock

December 4, 2023

Thousands could have been saved during the pandemic with expanded use of convalescent plasma

A new study led by researchers at Johns Hopkins Bloomberg School of Public Health estimates that thousands of lives could have been saved during the

October 4, 2024

Subcutaneous drugs grant a new lease on life to checkpoint inhibitors – Pharmaceutical Technology

As per Roche, Tecentriq SC can be administered in seven minutes compared to 30–60 minutes for the intravenous formulation. Image Credit: CI Photos / Shutterstock.

September 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.